Passage BIO PASG 深 沪
交易中 05-19 12:04:56 美东时间
5.06
-0.060
-1.17%
华盛通- 最 高5.06
- 今 开5.05
- 成交量 1341股
- 最 低 5.03
- 昨 收 5.12
- 总市值 1623.15万
- 52周最高 20.00
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 3.935
- 委 比 55.56%
- 总股本 320.78万
- 历史最高 764.60
- 量 比 0.05
- 振 幅 0.59%
- 历史最低 3.935
- 每 手 1
- 风险率 2.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
TD Cowen Downgrades Passage Bio to Hold
TD Cowen analyst Brendan Smith downgrades Passage Bio (NASDAQ:PASG) from Buy to Hold.
04-22 00:21
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis April 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CNX Resources, P&G and Prologis on Tuesday. HIGHLIGHTS * CNX Resources Corp CNX.N : Gerdes Energy Research raise
04-21 16:08
Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent Type C meeting
04-20 19:08
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Passage Bio reported interim data from its Phase 1/2 upliFT-D trial of PBFT02 for FTD-GRN, showing reduced brain atrophy and stabilized plasma NfL levels compared to natural history. FDA feedback indicated a randomized controlled trial is required for registration, prompting the company to evaluate next steps. Passage Bio also initiated a strategic review to maximize shareholder value, engaging Wedbush PacGrow as a financial advisor.
04-20 11:00
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30
Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.
03-31 21:58
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway
Passage Bio ( ($PASG) ) has issued an announcement. On March 4, 2026, Passage B...
03-10 19:55
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
03-05 03:01
